Cidara Therapeutics, Inc.
CDTX
Rangering i aksjer
#3185
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Aksjekurs
$221.38
Sist synkronisert: 2026-01-08
Markedsverdi
$5.61B
Endring (1 dag)
0.00%
Endring (1 år)
120.15%
Land
US
Handel Cidara Therapeutics, Inc. (CDTX)
Kategori
Healthcare
Antall utestående aksjer for Cidara Therapeutics, Inc. (CDTX)
Antall utestående aksjer per September 2025: 15.55M
Ifølge Cidara Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 15.55M. Ved slutten av December 2023 hadde selskapet 4.37M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Cidara Therapeutics, Inc. (CDTX) fra 2012 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 15.55M | 144.86% |
| 2024 | 6.35M | 45.25% |
| 2023 | 4.37M | 25.15% |
| 2022 | 3.49M | 33.24% |
| 2021 | 2.62M | 26.16% |
| 2020 | 2.08M | 38.83% |
| 2019 | 1.50M | 15.71% |
| 2018 | 1.29M | 47.82% |
| 2017 | 875.04K | 20.79% |
| 2016 | 724.45K | 5.22% |
| 2015 | 688.48K | 1,579.52% |
| 2014 | 40.99K | 153.29% |
| 2013 | 16.18K | -8.65% |
| 2012 | 17.72K | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 1,533.07% |
US
|
|
| 396.00M | 2,447.05% |
US
|
|
| 478.91M | 2,980.33% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 299.97% |
NL
|
